School of Human Sciences, Faculty of Education, Health and Human Sciences
London, SE10 9LS, United Kingdom
NCT Number: NCT06451978
Background: Nature positively affects people living with dementia. However, there are a lack of nature-based interventions for people living with mild cognitive impairment or dementia who reside in the community.
Aim: This study is testing a caregiver-led nature-based intervention, which has been co-developed with people living with dementia, supporters/caregivers and professionals, and the study design and set-up will also be evaluated. The results will help provide evidence for whether or not to carry out a larger study in the future and will also contribute to the evidence of nature-based interventions for people living with mild cognitive impairment or dementia.
Methods: People from the NHS and charities with a diagnosis of mild cognitive impairment or dementia, and their supporters/caregivers (this pair of participants are called a 'dyad') will be approached. The PhD researcher and dyads will meet to discuss the information sheet, answer any questions, then if they'd like to take part, dyads will each complete a consent form and questionnaire asking about demographics, mental health, and service use. A computer will then randomly assign the dyads into the intervention group or waitlist-control group (who will receive the intervention at the end of the study). Supporters/caregivers in the intervention group will attend a one-off online training session on how to use the manual.
The intervention involves 8 weekly sessions of nature-based activities, including a session evaluation sheet to complete for each session. The PhD researcher will call the supporters/caregivers twice during the intervention to check in. At the end of the intervention, dyads will complete another questionnaire each, and then those in the waitlist-control group will have the opportunity to take part in the intervention. There is also an optional interview that dyads can take part in to talk about their experience of the intervention and the study set-up.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Interventional
Not applicable
London, SE10 9LS, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
People living with dementia or mild cognitive impairment (PLWD/MCI)
Supporter/caregiver
Exclusion criteria
People living with mild cognitive impairment or dementia
The nature-based intervention is a manualised, caregiver-led intervention consisting of a physical manual comprising of 8 sessions of 8 different nature-based activities. It is designed for the person living with dementia or mild cognitive impairment and their caregiver to carry out the sessions together, either in their own home or out in a local area of nature.
Time frame: Post-intervention - 8 weeks after the baseline
As measured by the Warwick-Edinburgh Mental Well-being Scale (WEMWBS) - 14-item. Minimum score = 14, maximum score = 70. Higher score means better wellbeing (better outcome).
Time frame: Post-intervention - 8 weeks after the baseline
As measured by the Patient Health Questionnaire-9 (PHQ-9). Minimum score = 0, maximum score = 27. Higher score means higher levels of depression (worse outcome).
Time frame: Post-intervention - 8 weeks after the baseline
As measured by the Generalised Anxiety Disorder-7 (GAD-7) Minimum score = 0, maximum score = 21. Higher score means higher levels of anxiety (worse outcome).
Time frame: Post-intervention - 8 weeks after the baseline
As measured by the Nature Relatedness Scale - 21-item (NR-21). Minimum score = 21, maximum score = 105. Higher score means higher connectedness to nature (neither better or worse outcome).
Time frame: Post-intervention - 8 weeks after the baseline
As measured using a non-validated questionnaire which was created by the researchers - this is called 'Medication Use'. The non-validated questionnaire asks for the name of the medication, dosage and dose frequency. No minimum or maximum score. Higher use of medication could mean worse outcome.
Time frame: Post-intervention - 8 weeks after the baseline
As measured using the Client Service Receipt Inventory (CSRI). No minimum or maximum score. Higher use of services could mean better or worse outcome.
Time frame: Post-intervention - 8 weeks after the baseline
as measured by the Addenbrooke's Cognitive Examination - ACE-III (UK Version A - 2017).
Minimum score = 0, maximum score = 100. Higher score means higher levels of cognition (better outcome).
Time frame: Post-intervention - 8 weeks after the baseline
As measured by the Gain in Alzheimer care Instrument (GAIN). Minimum score = 0, maximum score = 40. Higher score means higher levels of gains in dementia caregiving (better outcome).
Time frame: Post-intervention - 8 weeks after the baseline
As measured using a non-validated questionnaire. No minimum or maximum score. Higher costs could mean worse outcome.
Harmony Jiang
Other
You, Me and Nature: A Randomised Pilot Study of a Manualised, Caregiver-led Nature-based Intervention to Improve the Wellbeing of People Living With Mild Cognitive Impairment or Dementia and Their Supporters or Caregivers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05532657
Aging, Brain Diseases
Hagerstown, Maryland, United States
View Trial DetailsNCT07651085
Alzheimer Disease, Basal Ganglia Diseases
Rome, Italy
View Trial DetailsNCT06704971
Alzheimer Disease, Brain Diseases
Palo Alto, California, United States
View Trial DetailsNCT05235113
Brain Diseases, Central Nervous System Diseases
Los Angeles, California, United States
View Trial Details